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LETTERS TO THE EDITOR
High Macrophage Migration Inhibitory Factor (MIF) Serum
Levels Associated with Extended Psoriasis
To the Editor:
Psoriasis is a common, chronic skin disease characterized by
persistent cutaneous in¯ammation, in®ltration by mononuclear
cells, and keratinocyte hyperproliferation (Nickoloff, 1999).
Various cytokines, growth factors, and chemical mediators play a
part in psoriatic skin lesions (Bonifati and Ameglio, 1999). MIF is
known to have diverse biologic functions as a proin¯ammatory
cytokine (Bucala, 1996), and also to be involved in the pathogenesis
of skin diseases such as atopic dermatitis (Shimizu et al, 1997). In
this study, we examined the serum macrophage migration
inhibitory factor (MIF) levels in psoriatic patients and the MIF
productivity of peripheral blood mononuclear cells (PBMC) to
investigate the potential role of MIF in the pathogenesis of this
vexing skin disease.
Serum samples were obtained from patients with untreated,
active psoriasis and, as controls, from healthy individuals. The MIF
content was measured using an enzyme-linked immunosorbent
assay (ELISA) as previously described (Shimizu et al, 1997). The
serum MIF content in patients with psoriasis (35.3 6 4.3 ng per
ml, mean 6 SEM) was signi®cantly higher than that in controls
(5.1 6 0.3 ng per ml) (Fig 1A). Serum MIF levels of psoriatic
patients treated with steroid ointment were correlated with the
clinical symptoms of psoriasis as assessed by the psoriatic area and
severity index (PASI) (Fig 1B). Eight patients with psoriasis (PASI
score: > 20) and nine healthy individuals were examined for MIF
production by PBMC. The PBMC (1 3 106 cells), prepared by
Ficoll-Plaque density gradient centrifugation, were stimulated with
either 10 mg per ml of concanavalin A (Con A) or left
unstimulated. After 48 h of culture, supernatants were collected
and subjected to MIF assay. The spontaneous MIF release into
culture media by PBMC from psoriatic patients (57.7 6 8.0 ng per
ml) was signi®cantly higher than that of controls (5.8 6 1.4 ng per
ml). Con A stimulation elevated the MIF content in the culture
media of PBMC from psoriatic patients signi®cantly, from
57.7 6 8.0 ng per ml to 77.9 6 11.2 ng per ml. That from
healthy individuals rose from 5.8 6 1.4 ng per ml to
20.5 6 1.2 ng per ml (Fig 2).
To elucidate the pathogenic mechanism of psoriasis, it is of
interest to investigate the source of elevated serum MIF in psoriatic
patients. MIF is expressed in various cells, including lymphocytes,
macrophages, and vascular endothelial cells (Bucala, 1996). We
previously reported that serum MIF is elevated in atopic dermatitis
(Shimizu et al, 1997) and BehcËet disease (Kitaichi et al, 1999). The
potential sources of MIF in atopic dermatitis and BehcËet disease are
considered to be PBMC and vascular endothelial cells, respectively.
MIF expression in epidermal layers is also upregulated by ultraviolet
B (UVB) irradiation (Shimizu et al, 1999), in which epidermal
layers might be the major source of MIF. We here demonstrated
that MIF production by PBMC of psoriatic patients was signi®-
cantly elevated. It was somewhat surprising that the production of
MIF protein was relatively decreased in psoriatic skin lesions in in
situ hybridization and western blotting (data not shown).
Accordingly, it is postulated that PBMC could be the major source
of elevated serum MIF content. In contrast, Steinhoff et al reported
a signi®cant increase of MIF immunoreactivity in suprabasal
keratinocytes, especially in those of the spinous layer, which
con¯icts with our results (Steinhoff et al, 1999). Although the
explanation for the difference between these two studies on
expression of MIF in psoriatic skin lesions remains unknown, it
may depend on the clinical course or the areas of examined skin
specimens, and whether these areas were exposed to sunlight.
The contribution of cytokines to the pathogenesis of psoriasis has
been widely studied, and activated T lymphocytes are generally
considered to play an important role in the expression of the
disease's pathologic features (Bonifati et al, 1994). MIF is known to
stimulate production of tumor necrosis factor (TNF)-a by
macrophages and vice versa (Bucala, 1996). It is hypothesized
that a positive in¯ammatory loop is generated by the interaction
between TNF-a and MIF, which may perpetuate a chronic
in¯ammatory state in psoriasis. On the other hand, the elevated
MIF level may cause keratinocyte hyperproliferation, because MIF
has the potential to stimulate cell growth (Mitchell et al, 1999).
With regard to keratinocyte hyperproliferation, several cytokines,
such as interleukin (IL)-8, are involved in the cell growth (Tuschil
et al, 1992). During the course of our MIF study, we found that
MIF could stimulate IL-8 production by cultured human
keratinocytes (data not shown), which may be responsible for
keratinocyte hyperproliferation. Taken together, these ®ndings
suggest that elevated MIF productivity of in®ltrating mononuclear
cells such as T lymphocytes promotes a lesional immunologic
disorder of psoriatic skin, which results in persistent in¯ammation
and keratinocyte proliferation.
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Figure 1. Serum MIF contents of psoriasis patients in relation to
clinical symptoms. (A) The serum level of MIF was measured by
ELISA speci®c for MIF as previously described (Shimizu et al, 1997) for
patients with psoriasis (n = 48, eight females and 40 males; mean age
44.9 6 2.4 y, ranging from 21 to 79 y) and healthy individuals (n = 87,
30 females and 57 males; mean age 45.0 6 1.2 y, ranging from 21 to
64 y). For this assay, recombinant human MIF was used to obtain a
standard curve, in which good linearity was demonstrated between MIF
contents (1±200 ng per ml) and absorbance. The serum MIF level was
signi®cantly increased in psoriatic patients compared with that in healthy
controls (*p < 0.0005). Student's t test was used to compare serum MIF
levels in psoriatic patients with those in the controls. (B) The severity of
psoriasis was assessed by means of PASI, in which the score ranges from
0 (no psoriatic symptoms) to 72 (maximum severity). PASI scores of the
patients examined in this study ranged from 3.2 to 41.4 (mean
17.9 6 1.4). Serum levels of psoriasis were correlated with the clinical
scores assessed by PASI (r = 0.735). The relation between PASI and MIF
was assessed using Pearson's linear regression analysis.
Figure 2 Effect of concanavalin A on MIF production of PBMC.
Eight patients with psoriasis (PASI score: > 20) and nine normal healthy
subjects were examined for MIF production by PBMC. PBMC were
prepared from heparinized peripheral blood by Ficoll-Plaque Plus density
gradient centrifugation. In brief, we collected cell layers at the density of
1.077 6 0.001 g per ml. Then the PBMC were washed three times
with sterile PBS. The PBMC (1 3 106 cells) were cultured in RPMI
1640 containing ampicillin (100 IU per ml), streptomycin (50 mg per
ml), and polymyxin B (30 mg per ml) using 24-well plates in a
humidi®ed atmosphere with 5% carbon dioxide at 37°C. The cells were
either stimulated with 10 mg per ml of Con A or left unstimulated. After
48 h of culture, supernatants were collected and frozen until the assay for
MIF by ELISA. MIF production of PBMC from psoriatic patients was
signi®cantly increased both with and without Con A (*p < 0.005).
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